Allergic conjunctivitis future or investigational therapies

Jump to navigation Jump to search

Allergic conjunctivitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Allergic Conjunctivitis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Allergic conjunctivitis future or investigational therapies On the Web

recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Allergic conjunctivitis future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Allergic conjunctivitis future or investigational therapies

CDC on Allergic conjunctivitis future or investigational therapies

Allergic conjunctivitis future or investigational therapies in the news

Blogs on Allergic conjunctivitis future or investigational therapies

Directions to Hospitals Treating Allergic conjunctivitis

Risk calculators and risk factors for Allergic conjunctivitis future or investigational therapies

Overview

Future or Investigational therapies

Calcineurin inhibitors

Mapracorat[5]

Omalizumab

References

  1. Tzu JH, Utine CA, Stern ME, Akpek EK (2012). "Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis". Cornea. 31 (6): 649–54. doi:10.1097/ICO.0b013e31822481c2. PMID 22378107.
  2. Cornish KS, Gregory ME, Ramaesh K (2010). "Systemic cyclosporin A in severe atopic keratoconjunctivitis". Eur J Ophthalmol. 20 (5): 844–51. doi:10.1177/112067211002000506. PMID 20491051.
  3. Virtanen HM, Reitamo S, Kari M, Kari O (2006). "Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study". Acta Ophthalmol Scand. 84 (5): 693–5. doi:10.1111/j.1600-0420.2006.00699.x. PMID 16965503.
  4. Reynolds NJ, Al-Daraji WI (2002). "Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology". Clin Exp Dermatol. 27 (7): 555–61. doi:10.1046/j.1365-2230.2002.01148.x. PMID 12464150.
  5. Baiula M, Spartà A, Bedini A, Carbonari G, Bucolo C, Ward KW; et al. (2011). "Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist". Mol Vis. 17: 3208–23. PMC 3244483. PMID 22194647.
  6. Vichyanond P (2011). "Omalizumab in allergic diseases, a recent review". Asian Pac J Allergy Immunol. 29 (3): 209–19. PMID 22053590.
  7. Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P (2009). "The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update". Respir Med. 103 (8): 1098–113. doi:10.1016/j.rmed.2009.03.008. PMID 19362459.
  8. Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG; et al. (2006). "Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis". J Allergy Clin Immunol. 117 (1): 134–40. doi:10.1016/j.jaci.2005.09.036. PMID 16387596.

Template:WH Template:WS